IOP and Medication Reduction in MIGS Procedures

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

NA

Study Classification

INTERVENTIONAL

Study Start Date

2020-01-06

Study Completion Date

2020-11-12

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of this research is to compare the efficacy of trabecular minimally invasive glaucoma surgery (MIGS) devices (iStent vs iStent Inject vs Hydrus) for intra ocular pressure (IOP) and anti-glaucoma medication reduction in open angle glaucoma.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent Inject) or Travoprost

NCT01444040

Open-angle Glaucoma

COMPLETED PHASE4

Comparing Effectiveness of the Hydrus Microstent (TM) to Two iStents to Lower IOP in Phakic Eyes

NCT02023242

Primary Open Angle Glaucoma Pseudoexfoliative Glaucoma Pigmentary Glaucoma

COMPLETED NA

Intraocular Pressure After Preserflo / Innfocus Microshunt Implantation vs Trabeculectomy

NCT04440527

Primary Open Angle Glaucoma Pseudoexfoliation Glaucoma

UNKNOWN NA

MIGS VS SLT Comparison in Glaucoma Patients

NCT02512133

Glaucoma

UNKNOWN PHASE3

iStent Inject in OAG Subjects on 2 Pre-op Topical Ocular Hypotensive Medications

NCT03478293

Primary Open Angle Glaucoma (POAG)

TERMINATED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Study Design Prospective Randomized Clinical Trial (Parallel Group Study)

Patients who fit inclusion criteria will be randomly assigned to one of the 3 parallel groups (one of the study surgical interventions combined with phacoemulsification) in the following order:

1. 1st Generation iStent, Trabecular Micro-Bypass Device (Glaukos Inc, San Clemente, CA).
2. 2nd Generation iStent, Trabecular Micro-Bypass Device (Glaukos Inc, San Clemente, CA).
3. Hydrus Microstent (Ivantis Inc, Irvine, CA). Blocked randomization will be used in 1:1:1 ratio to provide balanced study groups. Allocation will be performed using a random number table.

Preoperative Evaluation of : Visual acuity, Slit lamp examination, IOP, Gonioscopy, Fundus Examination, Central corneal thickness (CCT), Endothelial Cell Count (ECC), Visual field, Retinal Nerve Fiber layer (RNFL) thickness by Optical Coherence Tomography (OCT) and Number and type of preoperative antiglaucoma medications.

Patients will be followed postoperatively at Day 1, Week 1, Months 1, 3, 6 and 12.

Medication Washout will be done at baseline, Months 6 and 12 to evaluate non-medicated IOP.

The duration of washout will be:

4 Weeks for Prostaglandin Analogues (PGA) and Beta Blockers (BB). 2 Weeks for Carbonic Anhydrase Inhibitors (CAI) and Alpha Agonists (AA).

The IOP measurements in the wash out visits:

will be performed according to 2-operator method to provide masking as described in Ocular Hypertension Treatment Study (OHTS) and Glaucoma World Association Guidelines.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Open Angle Glaucoma Primary Open Angle Glaucoma Pigmentary Glaucoma Pseudoexfoliation Glaucoma in Both Eyes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

iStent

iStent Trabecular Bypass Device (to lower intraocular pressure) combined with Phacoemulsification (to remove cataract and insert intraocular lens) Eye Surgery

Group Type ACTIVE_COMPARATOR

Glaucoma and Cataract Surgery

Intervention Type PROCEDURE

Patients requiring combined cataract and glaucoma surgery will be randomized to either iStent, iStent Inject or Hydrus (to lower intraocular pressure) combined with Phacoemulsification (to remove cataract and insert intraocular lens) Eye Surgery

iStent Inject

iStent Inject Trabecular Bypass Device (to lower intraocular pressure) combined with Phacoemulsification (to remove cataract and insert intraocular lens) Eye Surgery

Group Type ACTIVE_COMPARATOR

Glaucoma and Cataract Surgery

Intervention Type PROCEDURE

Patients requiring combined cataract and glaucoma surgery will be randomized to either iStent, iStent Inject or Hydrus (to lower intraocular pressure) combined with Phacoemulsification (to remove cataract and insert intraocular lens) Eye Surgery

Hydrus

Hydrus Trabecular Bypass Device (to lower intraocular pressure) combined with Phacoemulsification (to remove cataract and insert intraocular lens) Eye Surgery

Group Type ACTIVE_COMPARATOR

Glaucoma and Cataract Surgery

Intervention Type PROCEDURE

Patients requiring combined cataract and glaucoma surgery will be randomized to either iStent, iStent Inject or Hydrus (to lower intraocular pressure) combined with Phacoemulsification (to remove cataract and insert intraocular lens) Eye Surgery

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Glaucoma and Cataract Surgery

Patients requiring combined cataract and glaucoma surgery will be randomized to either iStent, iStent Inject or Hydrus (to lower intraocular pressure) combined with Phacoemulsification (to remove cataract and insert intraocular lens) Eye Surgery

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 1\. Adult male or female aged 40 years or more. 2. Patients able and willing to provide informed consent. 3. Patients having Visually Significant Age Related Cataract with Mild to Moderate Open Angle Glaucoma (OAG) on topical anti-glaucoma medication with or without previous Selective Laser Trabeculoplasty (SLT) ), including:

1. Primary open angle glaucoma (POAG).
2. Pigmentary glaucoma.
3. Pseudoexfoliative glaucoma. 4. Patients should be candidate for safe mediaction wash out in the opinion of the investigator.

* The diagnosis of glaucoma is confirmd by optic nerve examination and the characteristic visual field defects on automated perimetry according to the American Academy of Ophthalmology (AAO) Definition and Criteria.
* The severity of glaucoma is classified using the Hodapp Parrish Anderson Visual Field Criteria depending on the Mean Deviation (MD):

1. Mild: MD no worse than -6 dB.
2. Moderate: MD worse than -6 but no worse than -12 dB.
3. Severe: MD worse than -12 dB.

2. Any prior glaucoma, corneal or vitreoretinal surgery.
3. Evidence of concomitant retinal, optic nerve, or neurological diseases affecting the visual field.
4. Abnormal angle anatomy.
5. Prior Argon Laser Trabeculoplasty (ALT), Laser Iridotomy or Iridoplasty.
6. Any systemic condition or medications affectiong IOP.
7. Corneal opacity, corneal dystrophy or central corneal thickness (CCT) less than 480 or more than 620 microns.
8. Exclusion from medications wash out according to the opinion of the investigator Or if any of the following is observed at any time point of the study:

1. Visual Field: Mean deviation worse than -12 dB.
2. Intraocular pressure: a treated IOP of greater than 24 mmHg.
3. Medications: using more than three medications.

Minimum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No